The pending deal was rumored overnight after a report from the Financial Times, spurring analysts to speculate that if true, ...

In today's Pharmalittle roundup, we're reading about a Lilly deal, a gene therapy shock for Duchenne families, and more.

Verve Therapeutics stock nearly doubled Tuesday after Eli Lilly agreed to buy the gene-editing company for up to $1.3 billion ...